Nasal Therapy Cuts Rhinovirus Load in Asthma Trial

Adults with asthma saw lower viral levels and fewer cold symptoms in an early, small study of an experimental nasal treatment.

Updated on Nov. 5, 2026 in Asthma

Bold flat-color editorial illustration of a glass vial with amber liquid and a pipette on a slate field, evoking an early nasal therapy study.
Ethris reported early trial results showing its experimental nasal therapy ETH47 reduced rhinovirus viral load in 50 adults with asthma. AI Illustration. Upload story photo >

Ethris reported topline phase 2a data for ETH47, an investigational nasal messenger RNA therapy, showing reduced rhinovirus load in adults with asthma. The randomized, placebo-controlled trial of 50 adults aged 18 to 65 years found a 40-fold reduction in peak viral load versus placebo, though the company did not report statistical significance for any outcome.

Why it matters

Rhinovirus infections are a common trigger of asthma flare-ups, so a therapy that blunts early viral replication in the airway could eventually change how these exacerbations are prevented. The results are early and small, so they signal a direction for research rather than a new option for patients.

This was a randomized, placebo-controlled phase 2a rhinovirus challenge trial in 50 adults aged 18 to 65 with symptomatic asthma, reporting a 40-fold lower peak viral load and 58% lower symptom score area under the curve with ETH47 versus placebo. Because no statistical tests or confidence intervals were released and the primary endpoint showed only a numerical trend, the findings are preliminary and should be read as early signals.

The players

Ethris

A biotechnology company developing messenger RNA therapies, including the investigational nasal candidate ETH47 for respiratory viral infections.

Imperial College London

A leading UK research university whose affiliated researchers contributed to the challenge study on rhinovirus infection.

The details

ETH47 is an investigational messenger RNA therapy that encodes interferon lambda, a signaling protein the body uses to strengthen antiviral defenses in the respiratory tract. Participants received a single nasal dose of either ETH47 or placebo one day before being challenged with rhinovirus A16. The therapy is designed to trigger local interferon lambda production in the airway, aiming to bolster innate defenses before the virus can multiply.

Timeline

  1. November 5, 2026: Ethris announced the topline phase 2a ETH47 data.

  2. Ethris plans a multiple-ascending-dose phase 1 study in patients with asthma and COPD.

Health Landscape

Rhinovirus is the most frequent trigger of asthma exacerbations, and most current asthma care manages symptoms rather than the viral infection itself. This early work tests an approach that aims to act on the virus directly in the airway, which would be a departure from the standard of care if later trials confirm it.

For people living with asthma, this is research to follow rather than a change to current treatment, since ETH47 is still investigational and not available outside clinical studies. If you notice that colds regularly set off your breathing symptoms, it is worth discussing your asthma action plan and infection prevention with your doctor.

The takeaway

The key insight is that researchers are testing whether an airway-directed therapy can blunt rhinovirus before it drives asthma flare-ups, but these results are early and unconfirmed. If colds reliably worsen your asthma, keep your action plan current and raise infection-prevention strategies with your clinician.

What happens next

Ethris plans a multiple-ascending-dose phase 1 study in patients with asthma and COPD, followed by a phase 2a rhinovirus challenge study in COPD and phase 2b field studies in both populations, though no dates for these were provided.

Further reading

For broader context on how the condition is managed day to day, explore our Asthma coverage.

More information

Read the full Ethris topline phase 2a ETH47 data release from the company.

Source note: This article includes information reported by Hcplive.